AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
| Revenue (Most Recent Fiscal Year) | $54.07B |
| Net Income (Most Recent Fiscal Year) | $7.04B |
| PE Ratio (Current Year Earnings Estimate) | 15.69 |
| PE Ratio (Trailing 12 Months) | 16.33 |
| PEG Ratio (Long Term Growth Estimate) | 1.29 |
| Price to Sales Ratio (Trailing 12 Months) | 3.98 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.32 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.21 |
| Pre-Tax Margin (Trailing 12 Months) | 16.90% |
| Net Margin (Trailing 12 Months) | 14.14% |
| Return on Equity (Trailing 12 Months) | 33.14% |
| Return on Assets (Trailing 12 Months) | 12.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.90 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.65 |
| Inventory Turnover (Trailing 12 Months) | 1.82 |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.18 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.24 |
| Earnings per Share (Most Recent Fiscal Year) | $4.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.49 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 3.10B |
| Free Float | -- |
| Market Capitalization | $218.77B |
| Average Volume (Last 20 Days) | 3.84M |
| Beta (Past 60 Months) | 0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 20.35% |
| Annual Dividend (Based on Last Quarter) | $2.06 |
| Dividend Yield (Based on Last Quarter) | 2.92% |